SURMOUNT-1
The Phase 3 trials that won approval, and the outcome studies that came afterward on cardiovascular, kidney and sleep-apnea endpoints.
What is SURMOUNT-1?
Tirzepatide at 5, 10 and 15 mg weekly against placebo, the main phase 3 trial, run across 2,539 participants carrying excess weight (Jastreboff et al., NEJM 2022, PMID 35658024).
The 15 mg arm averaged 20.9% loss across 72 weeks. That result turned tirzepatide into a drug people request by name.
Read more:
GLP Watchdog writes these definitions from FDA labels and peer-reviewed PubMed literature.
Where SURMOUNT-1 comes up on this site
On GLP Watchdog, SURMOUNT-1 comes up in 9 research articles and 4 tools.
Research that discusses it
- GLP-1 Hair Loss and Muscle Loss: What Was Measured
- Tirzepatide Week by Week: What the SURMOUNT Trials Recorded
- Which Zepbound Dose Works Best? 5, 10 and 15 mg Compared in the Trials
- GLP-1 Drugs and Cholesterol: What Happens to LDL, HDL and Triglycerides
- How Zepbound Works: Tirzepatide's Two Receptors, Appetite and Fat Loss
- AOD-9604: What the Evidence Shows
- All 9 articles are on the research page
Tools that use it
Other terms under Major trials
Where the evidence lives
- The full GLP-1 glossary (150 terms, 8 categories)
- Research articles — written from primary sources
- Tools and calculators
- Compare GLP-1 telehealth providers